Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ebp1 isoforms distinctively regulate cell survival and differentiation.

Zhixue Liu1, Jee-Yin Ahn, Xia Liu

  • 1Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 615 Michael Street, Atlanta, GA 30322, USA.

Proceedings of the National Academy of Sciences of the United States of America
|July 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the pathological tau N368 fragment: A pharmacological perspective on a novel immunotherapy for Alzheimer's disease.

Pharmacological research·2026
Same author

DeepDrugDiscovery identifies blood-brain barrier permeable autophagy enhancers for Alzheimer's disease.

Nature biomedical engineering·2026
Same author

C/EBPβ dictates postmenopausal FSHβ transcription and blockade of AEP/C/EBPβ pathway alleviates osteoporosis.

Bone research·2026
Same author

Galectin-9 activates the TLR4-NLRP3 inflammasome pathway and promotes tau pathology in Alzheimer's disease.

Brain, behavior, and immunity·2025
Same author

Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments.

Neuron·2025
Same author

Asparagine endopeptidase (AEP) inhibitor formulation via zein-based nanoparticle improves the therapeutic efficacy toward Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025

ErbB3 receptor-binding protein 1 (Ebp1) has two isoforms, p48 and p42, that distinctly control cancer cell survival and differentiation. Ebp1 isoforms differentially regulate cell fate, offering new therapeutic targets.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Signal Transduction

Background:

  • ErbB3 receptor-binding protein 1 (Ebp1) is known to inhibit cancer cell proliferation and induce differentiation.
  • Ebp1 interacts with nuclear Akt, preventing DNA fragmentation by inhibiting caspase-activated DNase.

Purpose of the Study:

  • To investigate the differential roles of Ebp1's two isoforms, p48 and p42, in mediating cell survival and differentiation.
  • To explore the specific interactions and signaling pathways influenced by each Ebp1 isoform.

Main Methods:

  • Utilized PC12 cell lines stably transfected with either p48 or p42 Ebp1 isoforms.
  • Investigated protein localization, apoptosis suppression, cell differentiation, neurite outgrowth, and Akt/MAPK pathway activation.
  • Examined epidermal growth factor (EGF) and nerve growth factor (NGF) mediated signaling.

Related Experiment Videos

Main Results:

  • The longer p48 isoform suppresses apoptosis and promotes proliferation, localizing in both cytoplasm and nucleus.
  • The shorter p42 isoform promotes differentiation and neurite outgrowth, primarily in the cytoplasm.
  • EGF stimulates p42 binding to ErbB3 via PKC-mediated phosphorylation; p48 does not bind ErbB3.
  • Akt activity is higher in p48 cells, while p42 cells exhibit more extensive NGF-induced neurite outgrowth.

Conclusions:

  • Ebp1 isoforms p48 and p42 exhibit distinct functions in regulating cell survival and differentiation.
  • Ebp1 isoform-specific signaling pathways, including Akt activation and ErbB3 binding, underlie their differential effects.
  • These findings suggest Ebp1 isoforms as potential targets for cancer therapy, modulating cell fate decisions.